DURHAM, N.C.--(BUSINESS WIRE)--ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, today announced Dovato (dolutegravir/ lamivudine) is now available in a blister pack in the U.S. Dovato is approved as a complete regimen to treat HIV-1 infection in adults with no antiretroviral (ARV) treatment history or to replace the current ARV regimen in those who are virologically suppressed (HIV-1 RNA <50 copies/mL) on a stable ARV regimen with no history ...

Pfizer (PFE) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term.Over the past month, shares of this drugmaker have returned -8.6%, compared to the Zacks S&P 500 composite's +4.6% change. During this period, the Zacks Large Cap Pharmaceuticals industry, which Pfizer falls in, has gained 5.3%. The key question now is: What could be the stock's future direction?While media releases or rumors ...

ATLANTA & NEW YORK--(BUSINESS WIRE)--The American Cancer Society (ACS) and Pfizer Inc. (NYE: PFE) today announced the launch of “ Change the Odds™: Uniting to Improve Cancer Outcomes,” a three-year initiative to bridge the gap in cancer care disparities. Through $15 million in funding from Pfizer, the initiative aims to improve health outcomes in medically underrepresented communities across the United States by enhancing awareness of and access to cancer screenings, clinical trial opportunities, and patien ...

Interestingly, there are no Big Pharma companies listed in the “Magnificent Seven.” Consequently, perfectly good companies like Pfizer (NYSE:PFE) are being overlooked, but that’s not bad news at all. If you appreciate a good value and like to collect dividends, stick around as today’s Pfizer stock analysis will bring you a “magnificent” pick for 2024. Now, I’m not going to claim that Pfizer is a problem-free company. It’s important to be aware of Pfizer’s challenges. However, without problems, there would b ...

Pfizer (PFE 0.22%) celebrates its 175th anniversary this year, so the pharma giant has a long history. But the drugmaker actually jumped into the global spotlight not long ago when it launched its blockbuster coronavirus vaccine, Comirnaty, followed by top-selling COVID treatment Paxlovid. These two products helped Pfizer reach a record $100 billion in annual revenue in 2022.The past year, though, has been a difficult one for the big pharma company. Demand for coronavirus products has been on the decline, w ...

Michael M. Santiago Written by Sam Kovacs. Introduction The pendulum of the market always swings. In just 2 years, Pfizer Inc. (NYSE:PFE) has gone from its ATH to the lowest price it has recorded in over 10 years. We've been watching it all come down, as by the time February 2022 hit, we had sold all of our Pfizer position, after having accumulated it in 2020 prior to the vaccine announcement (source here and here). When in December 2021, we said selling PFE was a good idea, this was met with quite a bit of ...

Pfizer Inc. (NYSE:PFE) Q4 2023 Results Conference Call January 30, 2024 10:00 AM ET Company Participants Francesca DeMartino - Chief Investor Relations Officer Albert Bourla - Chairman and Chief Executive Officer David Denton - Chief Financial Officer Aamir Malik - Executive VP & Chief U.S. Commercial Officer Alexandre de Germay - Executive VP & Chief International Commercial Officer Mikael Dolsten - Chief Scientific Officer and President of Research & Development Chris Boshoff - Executive VP & Chief Oncolo ...

Shares of Pfizer (PFE -0.64%) jumped as much as 3.2% higher on Tuesday morning before giving up all of the gains and then some. The pharma stock was down by 0.6% as of 12:05 p.m. ET.These gyrations came after Pfizer announced its fourth-quarter and full-year results before the opening bell. The company reported Q4 revenue of $14.2 billion. Although this was a 41% year-over-year decline, it still topped Wall Street's consensus revenue estimate of $13.3 billion.Pfizer posted a Q4 loss of nearly $3.4 billion, ...

For the quarter ended December 2023, Pfizer (PFE) reported revenue of $14.25 billion, down 41.3% over the same period last year. EPS came in at $0.10, compared to $1.14 in the year-ago quarter.The reported revenue represents a surprise of -0.80% over the Zacks Consensus Estimate of $14.36 billion. With the consensus EPS estimate being -$0.19, the EPS surprise was +152.63%.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine th ...

Pfizer (PFE) reported fourth-quarter 2023 adjusted earnings per share of 10 cents in contrast to the Zacks Consensus Estimate of a loss of 19 cents per share. In the year-ago quarter, the company had recorded earnings of $1.41 per share.Revenues came in at $14.25 billion, down 41% from the year-ago quarter on a reported basis, reflecting an operational decline of 42% but a currency benefit of 1%. Total revenues missed the Zacks Consensus Estimate of $14.37 billion.The revenue decline, as expected, was due t ...